Smith & Nephew plc (NYSE:SNN) Given Consensus Rating of “Moderate Buy” by Brokerages

Smith & Nephew plc (NYSE:SNN) has been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company.

Several analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Smith & Nephew in a report on Wednesday, July 24th. They issued a “buy” rating for the company. UBS Group upgraded shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a report on Wednesday, June 5th. Finally, StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday.

Hedge Funds Weigh In On Smith & Nephew

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNN. Seed Wealth Management Inc. acquired a new position in Smith & Nephew in the 4th quarter valued at $213,000. International Assets Investment Management LLC bought a new stake in shares of Smith & Nephew in the 4th quarter valued at approximately $716,000. Clean Yield Group boosted its stake in Smith & Nephew by 2.8% in the fourth quarter. Clean Yield Group now owns 214,252 shares of the medical equipment provider’s stock valued at $5,845,000 after acquiring an additional 5,805 shares during the period. Allworth Financial LP lifted its position in Smith & Nephew by 65.8% in the 4th quarter. Allworth Financial LP now owns 1,878 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 745 shares during the last quarter. Finally, Bleakley Financial Group LLC boosted its position in shares of Smith & Nephew by 26.0% during the fourth quarter. Bleakley Financial Group LLC now owns 11,865 shares of the medical equipment provider’s stock worth $324,000 after buying an additional 2,451 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew Stock Down 3.3 %

Shares of NYSE:SNN opened at $29.44 on Thursday. The company has a quick ratio of 0.72, a current ratio of 1.77 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average price is $26.62 and its 200-day moving average price is $26.40. Smith & Nephew has a 1 year low of $21.52 and a 1 year high of $31.13.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.